Alopecia areata and relationship with stressful events in children.

’Cetatea Histria’ Polyclinic, Bucharest, Romania.
Journal of the European Academy of Dermatology and Venereology (Impact Factor: 2.69). 05/2008; 23(1):107-9. DOI: 10.1111/j.1468-3083.2008.02748.x
Source: PubMed
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background  Alopecia areata (AA) is an autoimmune disease affecting about 2% of the population, which has a considerable impact on quality of life (QoL). There are no disease-specific questionnaires to assess QoL in patients suffering from AA. Objective  To validate a new disease-specific questionnaire for AA, named AA-QLI, and to compare the consequent Quality of Life Index (QLI) with the commonly known Dermatology Life Quality Index (DLQI) to verify if it can provide a more comprehensive tool for patients. Methods  A total of 50 patients affected by AA were administered both the AA-QLI, created by us, and the well-known DLQI. With the aim to detect suitable QLI, we propose to use two multivariate analyses: •  a principal component analysis approach on the data collected with both questionnaires to compare their capability to measure the QoL; •  a structural equation modelling on our AA-QLI to identify which category of symptoms mostly affects the QoL. Results  The scores of both the questionnaires are quite close, except for a few cases. Statistical analysis shows a higher specificity of the AA-QLI for evaluating QoL. Among the three areas in which AA-QLI is divided, 'Relationship' has a major impact on the QLI, followed by 'Subjective symptoms'; 'Objective signs' has a lower weight on the QLI. Conclusion  AA-QLI is a good instrument to evaluate the real impact of AA on QoL. It can be helpful both for the physician and for the patient.
    Journal of the European Academy of Dermatology and Venereology 07/2012; · 2.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Alopecia areata (AA) is characterized by rapid and complete hair loss in one or multiple areas of the scalp. Stress is an important triggering factor in AA. AIM: To identify the inhibitory effect of tianeptine on catagen induction in C57BL/6 mice with AA-like lesions induced by ultrasonic wave stress (UWS). METHODS: The mice were divided into four groups. Group 1 received oral tianeptine before and after UWS; group 2 received oral tianeptine only after UWS; group 3 was given UWS treatment only; and group 4 (negative control group) was not given any treatment. Phototrichigraphy and dermatoscopy were used for assessment. Histological analysis was performed using haematoxylin and eosin, toluidine blue, Masson trichrome and Verhoeff-van Gieson stains. Immunohistochemical analysis was also performed. The level of apoptosis and expression of neuropeptides in the skin were assessed by terminal deoxynucleotidyl transferase dUTP nick end labelling and immunofluorescence assays. RESULTS: Mice in group 1 had an increased rate of hair growth and greater hair-shaft thickness compared with mice in groups 2 and 3. In addition, mice in group 1 had a higher number of anagen hair follicles, increased synthesis of collagen and elastic fibres, decreased mast-cell degranulation, reduction in cell apoptosis in hair follicles, and recovery of vitamin D receptor expression. Expression of neuropeptides (substance P, calcitonin gene-related peptide) was not altered. CONCLUSIONS: Tianeptine might play a role in suppressing catagen induction in a stress-induced AA mouse model.
    Clinical and Experimental Dermatology 04/2013; · 1.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Objective: We sought to determine whether anti-depressive therapy could enhance the efficacy of dermatological treatment in alopecia areata patients who suffer from major depressive disorder. Methods: Sixty patients were enrolled in the study. Thirty patients with alopecia who were diagnosed with major depressive disorder received 20 mg/day citalopram and 5 mg/ml triamcinolone injection every 4 weeks, up to six injections, and 30 patients received only triamcinolone injection each month for 6 months using a simple random method. Results: The mean diameter of the alopecic patches in the triamcinolone injection only group versus the combined treatment group [psychiatric (citalopram) plus dermatologic treatment] before treatment was 2.7 ± 0.7 (mean ± SD) and 2.5 ± 1.8, respectively, with no statistically significant differences (Mann- Whitney, P=0.08). After 6 months of therapy, the mean diameter of patches reached 1.6 ± 1 and 0.54 ± 0.97 in the triamcinolone injection only group and the combined treatment groups, respectively (Mann- Whitney, P<0.0001). Discussion: The results of this study showed that anti-depressive treatment might help to improve alopecia areata in patients with major depressive disorder.
    Journal of Dermatological Treatment 01/2013; · 1.50 Impact Factor